Works in Cancer Chemotherapy & Pharmacology, 2023, Vol 92, Issue 2

Results: 8

A case report of typhlitis during novel use of ropidoxuridine–capecitabine–radiotherapy for treatment-naïve rectal cancer.

Published in:

2023

By:

Kunos, Charles A.;
Piekarz, Richard;
Collins, Jerry M.;
Kinsella, Timothy J.

Publication type:

Case Study

Adavosertib (AZD1775) does not prolong the QTc interval in patients with advanced solid tumors: a phase I open-label study.

Published in:

Cancer Chemotherapy & Pharmacology, 2023, v. 92, n. 2, p. 141, doi. 10.1007/s00280-023-04555-2

By:

Någård, Mats;
Ah-See, Mei-Lin;
Strauss, James;
Wise-Draper, Trisha;
Safran, Howard P.;
Nadeau, Laura;
Edenfield, William J.;
Lewis, Lionel D.;
Rekić, Dinko;
Dota, Corina;
Ottesen, Lone H.;
Li, Yan;
Mugundu, Ganesh M.

Publication type:

Article

The role of alternative splicing in lung cancer.

Published in:

Cancer Chemotherapy & Pharmacology, 2023, v. 92, n. 2, p. 83, doi. 10.1007/s00280-023-04553-4

By:

Ning, Xuelian;
Fu, Zitong;
Zhang, Jing;
Gao, Shuangshu;
Cui, Zihan;
Cong, Mingqi;
Guo, Qingyu;
Sun, Xixi;
Li, Jing;
Zhang, Minghui;
Wang, Shuoshuo

Publication type:

Article

Influence of age on pharmacokinetics of capecitabine and its metabolites in older adults with cancer: a pilot study.

Published in:

Cancer Chemotherapy & Pharmacology, 2023, v. 92, n. 2, p. 135, doi. 10.1007/s00280-023-04552-5

By:

Shafiei, Mohsen;
Galettis, Peter;
Beale, Philip;
Reuter, Stephanie E.;
Martin, Jennifer H.;
McLachlan, Andrew J.;
Blinman, Prunella

Publication type:

Article

Pharmacology and pharmacokinetics of elacestrant.

Published in:

Cancer Chemotherapy & Pharmacology, 2023, v. 92, n. 2, p. 157, doi. 10.1007/s00280-023-04550-7

By:

Beumer, Jan H.;
Foldi, Julia

Publication type:

Article

Osthole inhibits malignant phenotypes and induces ferroptosis in KRAS-mutant colorectal cancer cells via suppressing AMPK/Akt signaling.

Published in:

Cancer Chemotherapy & Pharmacology, 2023, v. 92, n. 2, p. 119, doi. 10.1007/s00280-023-04549-0

By:

Zhou, Xinghua;
Kang, Jian;
Zhang, Liangliang;
Cheng, Yue

Publication type:

Article

Phase I trial of intravenous fenretinide (4-HPR) plus safingol in advanced malignancies.

Published in:

Cancer Chemotherapy & Pharmacology, 2023, v. 92, n. 2, p. 97, doi. 10.1007/s00280-023-04543-6

By:

Boulter, Alexis C.;
Maurer, Barry J.;
Pogue, Meredith;
Kang, Min H.;
Cho, Hwangeui;
Knight, Amanda;
Reynolds, C. Patrick;
Quick, Donald;
Awasthi, Sanjay;
Gerber, David E.

Publication type:

Article

A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation.

Published in:

Cancer Chemotherapy & Pharmacology, 2023, v. 92, n. 2, p. 107, doi. 10.1007/s00280-023-04545-4

By:

Piha-Paul, Sarina A.;
Tseng, Chieh;
Tran, Hai T.;
Gao, Meng;
Karp, Daniel D.;
Subbiah, Vivek;
Tsimberidou, Apostolia Maria;
Kawedia, Jitesh D.;
Fu, Siqing;
Pant, Shubham;
Yap, Timothy A.;
Morris, Van K.;
Kee, Bryan K.;
Blum Murphy, Mariela;
Lim, JoAnn;
Meric-Bernstam, Funda

Publication type:

Article